Естонія - естонська - Ravimiamet

ucb pharma oy finland - levotsetirisiin - õhukese polümeerikattega tablett - 5mg 90tk; 5mg 15tk; 5mg 10tk; 5mg 14tk; 5mg 5tk; 5mg 60tk; 5mg 20tk; 5mg 70tk; 5mg 100tk; 5mg 28tk; 5mg 40tk; 5mg 4tk; 5mg 7tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - levotsetirisiin - suukaudne lahus - 0,5mg 1ml 200ml 1tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - tsetirisiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 7tk; 10mg 1tk; 10mg 10tk; 10mg 5tk; 10mg 60tk; 10mg 15tk; 10mg 21tk; 10mg 45tk; 10mg 20tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - tsetirisiin - suukaudsed tilgad, lahus - 10mg 1ml 20ml 1tk; 10mg 1ml 10ml 1tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - pseudoefedriin+tsetirisiin - toimeainet prolongeeritult vabastav tablett - 120mg+5mg 14tk; 120mg+5mg 28tk

Естонія - естонська - Ravimiamet

curium finland oy - fludeoksüglükoos (18f) - süstelahus - 250mbq 1ml 10ml 1tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - tsetirisiin - suukaudne lahus - 1mg 1ml 150ml 1tk; 1mg 1ml 75ml 1tk; 1mg 1ml 100ml 1tk; 1mg 1ml 200ml 1tk

Естонія - естонська - Ravimiamet

ucb pharma oy finland - piratsetaam - õhukese polümeerikattega tablett - 800mg 60tk; 800mg 90tk

Європейський Союз - естонська - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Європейський Союз - естонська - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - rinnanäärmed - endokriinse ravi, anti-östrogeene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pre - või perimenopausal naiste kombineeritud ravi palbociclib tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.